Drugs / NDX-3324
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05757856 | Jan 2023 → May 2025 | eosinophilic esophagitis | NexEos Diagnostics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDX-3324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05757856 ↗ |
| Route | Oral | “orally administered NDX-3315 or NDX-3324” NCT05757856 ↗ |